Glucose as a prognostic factor in ovarian carcinoma
| Autor: | Bridget Zimmerman, David M. Lubaroff, Donald M. Lamkin, Douglas R. Spitz, Anil K. Sood, Daniel J. Lenihan, Mian M.K. Shahzad, Eileen H. Shinn, Susan K. Lutgendorf, Koen DeGeest |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Blood Glucose Oncology Cancer Research medicine.medical_specialty Glucose uptake Disease-Free Survival Article Internal medicine Preoperative Care Humans Medicine Survival rate Survival analysis Aged Ovarian Neoplasms biology business.industry Hazard ratio Glucose transporter Cancer Middle Aged Prognosis medicine.disease Survival Analysis Endocrinology biology.protein Female GLUT1 business Ovarian cancer |
| Zdroj: | Cancer. 115:1021-1027 |
| ISSN: | 1097-0142 0008-543X |
| Popis: | BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma. Cancer 2009. © 2009 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text